Editorially Independent content supported with advertising by Genentech
Yasha S. Modi, MD
Show Description +
In a second case involving a large pigment epithelial detachment (PED), Yasha S. Modi, MD, presents the case of a 75-year-old patient who presents for a cataract evaluation. After a single injection of bevacizumab (Avastin, Genentech), the patient returned with significant anatomic complications. Will switching to aflibercept 2 mg (Eylea, Regeneron) change anything? And is there even a relationship between administration of therapy and formation of anatomic complications?
Posted: 1/15/2024
Yasha S. Modi, MD
In a second case involving a large pigment epithelial detachment (PED), Yasha S. Modi, MD, presents the case of a 75-year-old patient who presents for a cataract evaluation. After a single injection of bevacizumab (Avastin, Genentech), the patient returned with significant anatomic complications. Will switching to aflibercept 2 mg (Eylea, Regeneron) change anything? And is there even a relationship between administration of therapy and formation of anatomic complications?
Posted: 1/15/2024
Please log in to leave a comment.